Ningzi Zang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ningzi Zang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Jiapeng Leng
College of Pharmacy, Liaoning University of Traditional Chinese Medicine
2 shared publicationsLijian Pang
First Clinical College, Liaoning University of Traditional Chinese Medicine
2 shared publicationsPin Li
First Clinical College, Liaoning University of Traditional Chinese Medicine
2 shared publicationsYingxu Wu
First Clinical College, Liaoning University of Traditional Chinese Medicine
2 shared publicationsYongming Liu
Department of Traditional Chinese Medicine Experimental Center, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
2 shared publicationsHao Yan
First Clinical College, Liaoning University of Traditional Chinese Medicine
1 shared publication
Latest Publications
- 25 October 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 191 (Pt 1) , 117601
Breaking the barrier: MMP2/HAase dual-triggered liposomal nanoplatform for enhanced tumor penetration and immunogenic cell death
- 25 October 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 191 (Pt 1) , 117601
Breaking the barrier: MMP2/HAase dual-triggered liposomal nanoplatform for enhanced tumor penetration and immunogenic cell death
- Open Access
- 30 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1817835
Bridging the gaps: the gut-lung axis and microbial metabolites in the pathogenesis and treatment of pulmonary fibrosis
Pulmonary fibrosis (PF) is a chronic interstitial lung disease characterized by structural damage to the lung parenchyma, excessive deposition of extracellular matrix (ECM), and irreversible decline in lung function. Current pharmacological treatments cannot effectively reverse fibrosis, highlighting an urgent need for novel therapeutic targets. Recently, the gut-lung axis and its bidirectional communication have received increasing attention for their roles in PF progression. Metabolites derived from gut microbiota, including short-chain fatty acids (SCFAs), bile acids, tryptophan metabolites, lipopolysaccharides (LPS), and trimethylamine N-oxide, regulate immune responses, modulate signaling pathways, influence epigenetic modifications, and maintain intestinal barrier integrity, thereby exerting bidirectional effects on PF. Protective metabolites primarily inhibit fibroblast activation and collagen deposition, whereas pathological metabolites promote fibrosis by inducing inflammatory responses and oxidative stress. Potential therapeutic strategies targeting the gut-lung axis include fecal microbiota transplantation (FMT), probiotic and dietary interventions, and Traditional Chinese Medicine (TCM). However, clinical applications face challenges such as donor standardization, immunological safety, and consistency of therapeutic efficacy. Critical limitations remain, including reliance on acute-injury animal models that inadequately represent the chronic, irreversible nature of human PF. Translating findings across distinct PF subtypes requires caution, as their genetic architectures, immune landscapes, and microbiome interactions may differ considerably. Additionally, the causal relationship between microbial dysbiosis and fibrosis remains unclear, and clinical translation currently lacks stratified intervention strategies based on biomarkers. Future research should prioritize large-scale longitudinal cohort studies, integrated multi-omics analyses, organoid models, and gut-lung chip platforms to identify key effector molecules and therapeutic targets, ultimately facilitating precise clinical interventions targeting the gut-lung axis.
- 30 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1817835
Open AccessBridging the gaps: the gut-lung axis and microbial metabolites in the pathogenesis and treatment of pulmonary fibrosis
Pulmonary fibrosis (PF) is a chronic interstitial lung disease characterized by structural damage to the lung parenchyma, excessive deposition of extracellular matrix (ECM), and irreversible decline in lung function. Current pharmacological treatments cannot effectively reverse fibrosis, highlighting an urgent need for novel therapeutic targets. Recently, the gut-lung axis and its bidirectional communication have received increasing attention for their roles in PF progression. Metabolites derived from gut microbiota, including short-chain fatty acids (SCFAs), bile acids, tryptophan metabolites, lipopolysaccharides (LPS), and trimethylamine N-oxide, regulate immune responses, modulate signaling pathways, influence epigenetic modifications, and maintain intestinal barrier integrity, thereby exerting bidirectional effects on PF. Protective metabolites primarily inhibit fibroblast activation and collagen deposition, whereas pathological metabolites promote fibrosis by inducing inflammatory responses and oxidative stress. Potential therapeutic strategies targeting the gut-lung axis include fecal microbiota transplantation (FMT), probiotic and dietary interventions, and Traditional Chinese Medicine (TCM). However, clinical applications face challenges such as donor standardization, immunological safety, and consistency of therapeutic efficacy. Critical limitations remain, including reliance on acute-injury animal models that inadequately represent the chronic, irreversible nature of human PF. Translating findings across distinct PF subtypes requires caution, as their genetic architectures, immune landscapes, and microbiome interactions may differ considerably. Additionally, the causal relationship between microbial dysbiosis and fibrosis remains unclear, and clinical translation currently lacks stratified intervention strategies based on biomarkers. Future research should prioritize large-scale longitudinal cohort studies, integrated multi-omics analyses, organoid models, and gut-lung chip platforms to identify key effector molecules and therapeutic targets, ultimately facilitating precise clinical interventions targeting the gut-lung axis.
- Open Access
- 26 February 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (2) , e70118
Viral Pathogens and Pulmonary Fibrosis: EMT‐Driven Mechanisms and Insights From Traditional Chinese Medicine
Idiopathic pulmonary fibrosis (IPF) is a serious progressive complication of the respiratory system, which is profoundly associated with persistent extracellular matrix (ECM) deposition, fibrosis, and disrupted tissue regeneration. Emerging evidence shows that epithelial–mesenchymal transition (EMT) acts as a key factor in the pathogenesis of this idiopathic interstitial lung disease by connecting long‐lasting epithelial damage to fibroblast accumulation and fibrotic processes. Viral pathogens, particularly emerging and re‐emerging viruses, such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), Influenza Virus, and Dengue Virus (DENV) and also those with oncogenic potential such as Epstein–Barr Virus (EBV), Cytomegalovirus (CMV), and Hepatitis C Virus (HCV), have been demonstrated to be significantly associated with impaired epithelial signalling, persistent inflammation, and EMT induction. This underscores the presence of potential mechanistic overlap between viral infections and fibrotic complications of the respiratory system. On the other hand, investigations have also suggested the capacity of Traditional Chinese Medicine (TCM) agents to modulate various EMT‐linked pathways, which are simultaneously involved in both viral infections and IPF development. These common signalling pathways include TGF‐β, Wnt/β‐catenin, PI3K/AKT, and NF‐κB signalling, acting as potential therapeutic targets against fibrotic complications such as IPF. The present review aims to comprehensively describe current evidence on the dynamic cross‐talk between viral pathogens, particularly SARS‐CoV‐2, Influenza Virus, and DENV, EMT, and lung fibrosis. Additionally, it critically discusses how TCM‐derived bioactive agents can interfere with these interconnected processes. This review elucidates the mechanistic basis and therapeutic potential of TCM compounds in lung fibrosis, considering the wider context of virus‐related EMT dysregulation.
- 26 February 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (2) , e70118
Open AccessViral Pathogens and Pulmonary Fibrosis: EMT‐Driven Mechanisms and Insights From Traditional Chinese Medicine
Idiopathic pulmonary fibrosis (IPF) is a serious progressive complication of the respiratory system, which is profoundly associated with persistent extracellular matrix (ECM) deposition, fibrosis, and disrupted tissue regeneration. Emerging evidence shows that epithelial–mesenchymal transition (EMT) acts as a key factor in the pathogenesis of this idiopathic interstitial lung disease by connecting long‐lasting epithelial damage to fibroblast accumulation and fibrotic processes. Viral pathogens, particularly emerging and re‐emerging viruses, such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), Influenza Virus, and Dengue Virus (DENV) and also those with oncogenic potential such as Epstein–Barr Virus (EBV), Cytomegalovirus (CMV), and Hepatitis C Virus (HCV), have been demonstrated to be significantly associated with impaired epithelial signalling, persistent inflammation, and EMT induction. This underscores the presence of potential mechanistic overlap between viral infections and fibrotic complications of the respiratory system. On the other hand, investigations have also suggested the capacity of Traditional Chinese Medicine (TCM) agents to modulate various EMT‐linked pathways, which are simultaneously involved in both viral infections and IPF development. These common signalling pathways include TGF‐β, Wnt/β‐catenin, PI3K/AKT, and NF‐κB signalling, acting as potential therapeutic targets against fibrotic complications such as IPF. The present review aims to comprehensively describe current evidence on the dynamic cross‐talk between viral pathogens, particularly SARS‐CoV‐2, Influenza Virus, and DENV, EMT, and lung fibrosis. Additionally, it critically discusses how TCM‐derived bioactive agents can interfere with these interconnected processes. This review elucidates the mechanistic basis and therapeutic potential of TCM compounds in lung fibrosis, considering the wider context of virus‐related EMT dysregulation.
- Open Access
- 8 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1735888
Effectiveness and safety of four drainage methods for lung abscess: a Bayesian network meta-analysis and systematic review
Objective: To compare the efficacy and safety of various pus drainage methods for lung abscess via network meta-analysis. Methods: Randomized controlled trials (RCTs) from PubMed, Embase, Scopus, Web of Science, VIP, Wanfang, and CNKI were searched up to April 2025. Study quality was assessed using the Cochrane Risk of Bias Tool (v5.4.0). Bayesian network meta-analysis was conducted using Rstudio (v4.4.1). Results: A total of 23 RCTs (1,453 patients) evaluating four drainage techniques were included. Effective rate: CT-guided percutaneous drainage + antibiotics ranked highest (77% probability), outperforming antibiotics alone (OR = 5.4) and conventional postural drainage + antibiotics (OR = 7.4). Hospital stay: Ultrasound-guided drainage + antibiotics ranked best (89% probability), significantly reducing stay versus conventional postural drainage + antibiotics (MD = –19 days). Symptom resolution: Ultrasound-guided drainage + antibiotics ranked highest for cough (SUCRA 97%) and fever resolution (SUCRA 97%). Lesion reduction: Modified postural drainage + antibiotics ranked highest (98% probability), surpassing conventional postural drainage + antibiotics (OR = 0.48) and antibiotics alone (OR = 0.15). Conclusion: Comprehensive analysis indicates that ultrasound-guided percutaneous drainage combined with antibiotics demonstrates the highest probability of improvement in key outcome measures, including time to fever resolution, length of hospital stay, and time to cough resolution, potentially showcasing a comprehensive potential for clinical benefit. CT-guided percutaneous drainage combined with conventional antibiotic therapy may be the most effective in terms of the effective rate, while modified postural drainage combined with conventional antibiotic therapy may be the most prominent in increasing the number of lesion reduction. Furthermore, conventional antibiotic therapy alone was inferior to pus drainage procedures combined with conventional antibiotics across multiple outcome measures and was associated with a higher incidence of adverse reactions. However, due to the limited number of available studies, these findings can only be considered preliminary. Future validation through a substantial number of multicenter, large-sample, double-blind randomized controlled trials is warranted. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251127786.
- 8 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1735888
Open AccessEffectiveness and safety of four drainage methods for lung abscess: a Bayesian network meta-analysis and systematic review
Objective: To compare the efficacy and safety of various pus drainage methods for lung abscess via network meta-analysis. Methods: Randomized controlled trials (RCTs) from PubMed, Embase, Scopus, Web of Science, VIP, Wanfang, and CNKI were searched up to April 2025. Study quality was assessed using the Cochrane Risk of Bias Tool (v5.4.0). Bayesian network meta-analysis was conducted using Rstudio (v4.4.1). Results: A total of 23 RCTs (1,453 patients) evaluating four drainage techniques were included. Effective rate: CT-guided percutaneous drainage + antibiotics ranked highest (77% probability), outperforming antibiotics alone (OR = 5.4) and conventional postural drainage + antibiotics (OR = 7.4). Hospital stay: Ultrasound-guided drainage + antibiotics ranked best (89% probability), significantly reducing stay versus conventional postural drainage + antibiotics (MD = –19 days). Symptom resolution: Ultrasound-guided drainage + antibiotics ranked highest for cough (SUCRA 97%) and fever resolution (SUCRA 97%). Lesion reduction: Modified postural drainage + antibiotics ranked highest (98% probability), surpassing conventional postural drainage + antibiotics (OR = 0.48) and antibiotics alone (OR = 0.15). Conclusion: Comprehensive analysis indicates that ultrasound-guided percutaneous drainage combined with antibiotics demonstrates the highest probability of improvement in key outcome measures, including time to fever resolution, length of hospital stay, and time to cough resolution, potentially showcasing a comprehensive potential for clinical benefit. CT-guided percutaneous drainage combined with conventional antibiotic therapy may be the most effective in terms of the effective rate, while modified postural drainage combined with conventional antibiotic therapy may be the most prominent in increasing the number of lesion reduction. Furthermore, conventional antibiotic therapy alone was inferior to pus drainage procedures combined with conventional antibiotics across multiple outcome measures and was associated with a higher incidence of adverse reactions. However, due to the limited number of available studies, these findings can only be considered preliminary. Future validation through a substantial number of multicenter, large-sample, double-blind randomized controlled trials is warranted. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251127786.